Investment analysts at StockNews.com initiated coverage on shares of AC Immune (NASDAQ: ACIU) in a report released Monday. The brokerage set a “hold” rating on the stock.
ACIU has been the subject of several other research reports. SVB Leerink cut their target price on shares of AC Immune from $15.00 to $10.00 and set an “outperform” rating for the company in a research note on Monday, July 11th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of AC Immune in a research note on Friday, June 17th.
ACIU opened at $2.79 on Monday. AC Immune has a fifty-two-week low of $2.06 and a fifty-two-week high of $8.14. The company has a debt-to-equity ratio of 0.01, a quick ratio of 13.28, and a current ratio of 13.28. The company has a fifty-day moving average of $3.27 and a two-hundred-day moving average of $3.47. The stock has a market capitalization of $233.11 million, a price-to-earnings ratio of -2.76, and a beta of 0.72.
AC Immune (NASDAQ: ACIU) released its quarterly earnings data on Thursday, July 28th. The company reported ($0.24) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.24). On average, research analysts expect AC Immune to post -1.01 earnings per share for the current year.
Large investors have recently bought and sold shares of the business. Virtus ETF Advisers LLC increased its holdings in AC Immune by 14.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 32,852 shares of the company’s stock, valued at $163,000, after acquiring an additional 4,158 shares in the last quarter. UBS Group AG increased its stake in AC Immune by 191.2% during the second quarter. UBS Group AG now owns 54,825 shares of the company’s stock, valued at $198,000, after purchasing an additional 36,000 shares during the last quarter. Metatron Capital SICAV plc bought a new position in shares of AC Immune during the fourth quarter worth about $218,000. GSA Capital Partners LLP bought a new position in shares of AC Immune during the fourth quarter worth about $362,000. Finally, Handelsbanken Fonder AB bought a new position in shares of AC Immune during the first quarter worth about $404,000. Institutional investors and hedge funds own 16.55% of the company’s stock.
AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products to prevent and treat neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in neurodegenerative diseases.